Antihypertensive activity of N-[(S)-1-(ethoxycarbonyl)-3-phenylpropyl]-L-Ala-L-Pro (MK-421), an orally active converting enzyme inhibitor.
D000284:Administration, Oral; D000803:Angiotensin I / Q000037:antagonists & inhibitors; D000806:Angiotensin-Converting Enzyme Inhibitors; D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects; D004151:Dipeptides / Q000494:pharmacology*; D004195:Disease Models, Animal; D004285:Dogs; D004359:Drug Therapy, Combination; D004656:Enalapril; D005260:Female; D006852:Hydrochlorothiazide / Q000627:therapeutic use; D006973:Hypertension / Q000188:drug therapy; D006977:Hypertension, Renal / Q000188:drug therapy; D008297:Male; D009392:Nephrectomy; D051381:Rats; D012083:Renin / Q000097:blood
D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D004151:Dipeptides; D006852:Hydrochlorothiazide; D004656:Enalapril; D000803:Angiotensin I; D012083:Renin